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Demographics of the Study Patents 
Age 62 f 6.4 years 
Sex (M/F) 20122 
Coronary Artery Disease 67% 
Left Ventricular Systolic Dysfunction (EF ~40%) 23% 
Diabetes 14% 
Current Smokers 44% 
Prior Stroke 15% 
Chronic Renal Insufficiency (Serum creatinine > 1.5mgldl) 15% 
Fontaine Stage Ilb 70% 
Fontaine Stage Ill 18% 
Fontaine Stage IV 12% 
Mean Ankle Brachial Index 0.3 * 0.2 
1199-201 Common Femoral Artery Percutaneous Intervention: 
Feasibility, Safety, and Clinical Outcomes 
Viiay G. Kalaria. Riyaz Bashir, Glenn Wang, Robert Schainfeld, Jeffrey Isner, Kenneth 
Rosenfield. St. Elizabeth’s Medical Center, Tufts University, Boston, MA. Krannert 
Institute of Cardiology, Indiana University, Indianapolis, IN 
Background: Common femoral artery (CFA) atherosclerotic lesions are traditionally 
treated surgically. We report our inittal experience of percutaneous intervention (PTA) for 
CFA disease. 
Methods: From January 1998 to December 2001,47 patients (53 limbs) undewent PTA 
of CFA lesions. Angiographlc (final diameter stenosis < 30%) and clinical success, proce- 
dural and clinical complications were noted for all the patients. Primary and secondary 
patency was determined using Duplex ultrasound or ankle-brachial index (ABI) criteria 
and life table method at 6 months and one year. 
Results: Procedure indication was Rutherford category 2-3 moderate-to-severe claudica- 
tion (70.2%), category 4 rest pain (8.5%), category 5-6 tissue loss (19.3%) and salvage 
of iatrogenic artery dissection (2%), respectively. Majority of the patients had ipsilateral 
Iliac disease (70%) and 38% had prior peripheral surgical revascularization. Angio- 
graphic success was achieved in 100% of patients and pre-diameter stenosis 77.4 +I/- 
14.9% was reduced to 22.4+1- 16.1%. Procedural complications included distal emboliza- 
tion (1.9%), and major hematomas (3.8%. all managed conservatively). None of the 
patients underwent emergency surgery or had procedure-related limb-loss. Pre-proce- 
dure ABI (0.61+ 0.18) improved at 6 month (0.72+ 0.16, p = 0.02) and one year 
(0.73+0.27, p = 0.06). Clinical symptoms improvement was moderate-to-marked (+2 to 
+3 scale) in 64%, and minimal (+l scale) in 15% of the patients. Primary and secondary 
patency rates were 87%, 97% at six-month, and 51%, 63% at one year, respectively. 
Conclusion: Early experience shows that CFA disease treatment with PTA is feasible 
and safe, and may serve as an alternative to surgery in selected patients. Favorable 
patency rates were noted in this small series of patients treated by experienced opera- 
tors. 
1199-202 Percutaneous intervention of Common Femoral Artery 
for the Treatment of Limb lschemia 
Huao A. Quintana, Jose A. Silva, Stephen R. Ramee, Stephen J. Jenkins, Tyrone J. 
Collins, Christopher J. White, Ochsner Clinic Foundation, New Orleans, LA 
Background: Significant atherosclerotic disease of the common femoral artery (CFA) 
occurs infrequently. It often represents an extension of aorta-iliac atherosclerotic dis- 
ease. Repolts of percutaneous intewentlon of this vessel an? scarce in the literature. 
Methods: Percutaneous angioplasty (PTA) (n=ll; 52%) with provisional stenting (n=9; 
48%) was performed in the CFA of 19 patients (pts) (age: 64.9+9.6 years, 65% males) 
and 20 vessels. The indication for the procedure was Rutheford class V: one patient 
(5.2%), class IV: 7 pts (36.6%), class III: 9 pts (47.4%), class II: 2 pts (10.5%). Procedural 
success was defined as final minimum diameter of < 30% and an increase in ankle-bra- 
chial index (ABI) z 0.15; and clmical success as procedural success and freedom from 
in-hospital amputation and death. 
Results: Procedural success was obtained in 18 pts (94.7%) and clinical swcess was 
attamed in 17 pts (89.5%). ABI improved from 0.54+0.21 at baseline, to 0.63+0.16 after 
the procedure (p=O.O02). At a mean follow up of 11.4+6 (range, 2-24 months), Rutheford 
class improved at least by one functional class in 17 patients (89.5%) (p=O.O36). No 
patient required amputation or died at follow up. One patient (5.3%) required an addi- 
tional ipsilateral fern-pop bypass and one patient required ipsilateral iliac PTA and stent- 
,ng. 
Conclusions: PTA with provisional stenting of the CFA in pts with significant ischemia of 
the lower extremitws, IS associated with an excellent procedural and clinical success and 
a low complication rats. 
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867-l Correlation Between Statin Therapy Before 
Percutaneous Coronary Intervention, Periprocedural 
Creatine Kinase-MB Release, and Mortality at Follow-Up 
Annapoorna S. Kink Paul Lee, Cristina A. Mitre, Ajay Agarwal, Shazia Mukaddam, 
Michael C. Kim, Samin K. Sharma, The Mount Sinai Medical Center, New York, NY, The 
University of Toronto, Toronto, ON, Canada 
Background - Statin therapy has been shown to reduce mortality in patients with coro- 
nary ariery disease. However, the effect of statin therapy before percutaneous coronary 
intervention (PCI) on acute and long-term outcome after PCI has not been well e&b- 
lished. 
Methods - We analyzed 4660 PCI patients for in-hospital events and l-year moltality 
and compared the results between patients receiving statin therapy (PS. n=2970, 63.7%) 
and no-statin therapy (NS, n=1690, 36.3%) prior to PCI. All patients had CK-MB and Tnl 
measured at baseline and 12-24 hrs after PCI. All PS patients continued statins after 
PCI. 
Results -Any CK-MB elevation was 15.4% versus 14.4% (p=O.37) in NS versus PS 
group. Troponin-I release, procedural complications, and clinical success rate were simi- 
lar in the 2 groups. At follow-up, pre-statin therapy was an independent predictor 
(HR=0.65, 95% Cl 0.45-0.93; p-zO.0007) of survival (Figure). Other important baseline 
predictors of mortality were LVEF (HR=1.20), age (HR=1.03), peripheral vascular dis- 
ease (tfR=1.35), symptomatic hearl failure (H&1.42), and renal failure (HR=2.01). 
There was no difference in follow-up Ml or revascularization. 
Conclusions- Statins have a beneficial effect on survival even in PCI patients. This sur- 
vival benefit is mediated by other pleiotropic effects of statins and not by reduction of 
peri-procedural enzyme release or follow-up Ml or revascularization. 
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867-2 Abciximab Readministration: Final Results of the 
Reopro” Readministration Registry 
Jean-Pierre Dery, Gregory A. Braden, A. Michael Lincoff, Dean J. Kereiakes, Kevin F. 
Browne. Thomas Little, Barry S. George, Mark 8. Effron, Maly Ann Mascelli. Maly Ann 
Langrall, Lakshmi Damaraju, Elliot S. Barnathan, James E. Tcheng, Duke University 
Medical Center, Durham, NC 
??ackground:Clinical outcomes of patients undergomg percutaneous coronary interven- 
tion can be improved by blocking platelet glycoprotein Ilb/llla with abciximab (ReoPro). 
Interim results of the Reopro Readministration Registry documented both efficacy and 
safety of abciximab readministration. The final results of this registry are presented. 
Methods: A total of 1342 patients receiving abciximab for at least a second time were 
recruited from 24 centers in the United States. The safety endpoints assessed wars the 
risks of hypersensitivity, major bleeding, thrombocytopenia (TCP), and human antichi- 
merit antibody (HACA) response. Event-free clinical ?.~ccess of the procedure was used 
to determine efficacy. 
Results: Procedural success was 98% overall, and was not influenced by the number of 
readministrations or by the presence of positive HACA titers prior to readministration 
(which occurred in 5.6%). There were no cases of anaphylaxis, only 5 minor allergic 
reactions, none of which required termination of the infusion. Major bleeding occurred in 
2.2%, including 1 (0.07%) mtracranial hemorrhage. TCP (cl00 x lo9 A and 25% 
decrease from baseline) developed in 5.0%, whereas profound TCP (~20 x lo9 A) 
occurred in 2.0%. The incidence of TCP tended to fall as the time between administra- 
tions lengthened. Having a positive HACA titer prior to readministration did not correlate 
with adverse clinical outcomes or bleeding, but was associated with an increased inci- 
